Commack, NY, United States of America

Xin Chen

This inventor holds 17 USPTO granted patents and 7 published patent applications and 6 EPO patents, primarily in Targeted Protein Degradation. Top assignees: Osi Pharmaceuticals, Inc., Arvinas Operations, Inc., Yale University. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xin Chen. Retrieved from https://idiyas.com/inventor/xin-chen-e8l956zr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 

% Patents Active = 70.6

 

Average Co-Inventor Count = 10.4

ph-index = 6

Forward Citations = 122(Granted Patents)


Location History:

  • Farmingdale, NY (US) (2010)
  • Commack, NY (US) (2011 - 2015)
  • Trumbull, CT (US) (2014 - 2022)

Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Androgen Receptor
Targeted Degradation
mTOR Inhibitors
Amino Pyrimidine
Fused Bicyclic
Kinase Inhibitors
Pyrrolo Compounds
Anticancer Compounds
Furo Compounds
Pyridine Derivatives
Pyrazines
Protein Targeting
17 patents (USPTO):Explore Patents

Title: **Innovator Spotlight: Xin Chen**

Introduction

Xin Chen is an accomplished inventor based in Commack, NY, United States. With a remarkable portfolio of 17 patents, he has made significant contributions to the field of biotechnology, particularly in the development of compounds that target the degradation of specific proteins. His pioneering work showcases a strong understanding of pharmacological activities associated with targeted protein modulation.

Latest Patents

Among his latest innovations, Xin Chen has patented two noteworthy discoveries. The first is focused on **Compounds and methods for the targeted degradation of androgen receptor**. This invention introduces bifunctional compounds that facilitate the degradation and inhibition of the Androgen Receptor, utilizing a VHL ligand to bind to the ubiquitin ligase, alongside a moiety that targets the androgen receptor. This innovative approach demonstrates a spectrum of pharmacological activities related to effective degradation.

The second patent involves **Compounds and methods for the enhanced degradation of targeted proteins**. Similar to his first innovation, this invention employs bifunctional compounds to modulate targeted ubiquitination, specifically as inhibitors for various polypeptides and proteins. The methodology positions the target protein close to the ubiquitin ligase, promoting its degradation. Both inventions underline Xin's expertise in developing compounds that bring transformative changes in biomedical applications.

Career Highlights

Xin Chen’s professional journey includes notable tenures at Osi Pharmaceuticals, Inc. and Arvinas Operations, Inc., where he applied his innovative expertise to advance drug discovery and development. His work in these organizations highlights his commitment to improving therapeutic strategies through cutting-edge research.

Collaborations

Throughout his career, Xin has worked with talented individuals, including Andrew Philip Crew and Jing Wang. Collaboration with such colleagues has fostered an environment of ingenuity, allowing Xin to further enhance his inventions and drive forward the frontiers of science.

Conclusion

Xin Chen stands out as a vital contributor to the field of biotechnology, with his extensive patent portfolio attesting to his inventive spirit. His latest patents, aimed at targeted protein degradation, signify a remarkable advancement in therapeutic methodologies. As an inventor, Xin continues to influence the scientific landscape, demonstrating the crucial role of innovation in addressing complex biomedical challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…